-
Je něco špatně v tomto záznamu ?
Human galectin-2: nuclear presence in vitro and its modulation by quiescence/stress factors
B Dvorankova, L Lacina, K Jr Smetana, M Lensch, JC Manning, S Andre, HJ Gabius
Jazyk angličtina Země Španělsko
NLK
Open Journal Systems (OJS)
od 2002
- MeSH
- adenokarcinom metabolismus MeSH
- biologické markery MeSH
- biologický transport MeSH
- buněčné jádro metabolismus MeSH
- buňky 3T3 MeSH
- financování organizované MeSH
- galektin 2 metabolismus MeSH
- imunohistochemie MeSH
- kokultivační techniky MeSH
- kultivační média bez séra MeSH
- lidé MeSH
- mitomycin farmakologie MeSH
- myši MeSH
- nádorové buněčné linie MeSH
- nádory tračníku metabolismus MeSH
- ultrafialové záření MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- myši MeSH
- zvířata MeSH
Galectins have the particular capacity to interact with distinct proteins, in addition to the typical reactivity of lectins with glycans. Therefore, they can be functionally active when residing at places other than the membrane or extracellular matrix. In fact, nuclear presence of galectins-1 and -3 is solidly documented but it is an open question whether these two cases are exceptional within this lectin family. Thus, galectin-2, which shares 43% sequence identity on the protein level with galectin-1, warrants study in this respect. Based on initial immunohistochemical evidence we herein address the issue as to whether this galectin can join the category of nuclear lectins. To do so we studied different types of cell in vitro using an antibody preparation free of cross-reactivity against other tested galectins. The immunocytochemical experiments revealed that galectin-2 was present in nuclei of murine 3T3 fibroblasts and also genetically engineered human colon carcinoma cells with stable ectopic expression. Transport of galectin-2 to the nucleus could be enhanced by physical (UV light), chemical (mitomycin C, serum withdrawal) or cell biological (coculture with stromal cells) treatment modalities. As a means of further characterizing the staining profile cytochemically, a series of markers with well-defined site of residency within the nuclear compartment was tested in parallel. Importantly, no colocalization with galectins-1 and -3 and the splicing factor SC35 was detectable, the former cases also serving as inherent specificity control. In contrast, a similarity was uncovered in the case of the promyelocytic leukemia (PML) protein as marker of PML nuclear bodies. In aggregate, nuclear localization is documented for galectin-2. This attribute should thus not be considered as an exceptional finding confined to galectins-1 and -3. That even closely related family members, here galectins-1 and -2, exhibit distinct intranuclear localization patterns gives ensuing research a clear direction.
- 000
- 00000naa 2200000 a 4500
- 001
- bmc10026229
- 003
- CZ-PrNML
- 005
- 20111210192257.0
- 008
- 101018s2008 sp e eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sp
- 100 1_
- $a Dvořánková, Barbora, $d 1955- $7 xx0076196
- 245 10
- $a Human galectin-2: nuclear presence in vitro and its modulation by quiescence/stress factors / $c B Dvorankova, L Lacina, K Jr Smetana, M Lensch, JC Manning, S Andre, HJ Gabius
- 314 __
- $a Charles University, 1st Faculty of Medicine, Institute of Anatomy, Prague, Czech Republic.
- 520 9_
- $a Galectins have the particular capacity to interact with distinct proteins, in addition to the typical reactivity of lectins with glycans. Therefore, they can be functionally active when residing at places other than the membrane or extracellular matrix. In fact, nuclear presence of galectins-1 and -3 is solidly documented but it is an open question whether these two cases are exceptional within this lectin family. Thus, galectin-2, which shares 43% sequence identity on the protein level with galectin-1, warrants study in this respect. Based on initial immunohistochemical evidence we herein address the issue as to whether this galectin can join the category of nuclear lectins. To do so we studied different types of cell in vitro using an antibody preparation free of cross-reactivity against other tested galectins. The immunocytochemical experiments revealed that galectin-2 was present in nuclei of murine 3T3 fibroblasts and also genetically engineered human colon carcinoma cells with stable ectopic expression. Transport of galectin-2 to the nucleus could be enhanced by physical (UV light), chemical (mitomycin C, serum withdrawal) or cell biological (coculture with stromal cells) treatment modalities. As a means of further characterizing the staining profile cytochemically, a series of markers with well-defined site of residency within the nuclear compartment was tested in parallel. Importantly, no colocalization with galectins-1 and -3 and the splicing factor SC35 was detectable, the former cases also serving as inherent specificity control. In contrast, a similarity was uncovered in the case of the promyelocytic leukemia (PML) protein as marker of PML nuclear bodies. In aggregate, nuclear localization is documented for galectin-2. This attribute should thus not be considered as an exceptional finding confined to galectins-1 and -3. That even closely related family members, here galectins-1 and -2, exhibit distinct intranuclear localization patterns gives ensuing research a clear direction.
- 650 _2
- $a buňky 3T3 $7 D016475
- 650 _2
- $a adenokarcinom $x metabolismus $7 D000230
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a biologické markery $7 D015415
- 650 _2
- $a biologický transport $7 D001692
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a buněčné jádro $x metabolismus $7 D002467
- 650 _2
- $a kokultivační techniky $7 D018920
- 650 _2
- $a nádory tračníku $x metabolismus $7 D003110
- 650 _2
- $a kultivační média bez séra $7 D016895
- 650 _2
- $a galektin 2 $x metabolismus $7 D037501
- 650 _2
- $a imunohistochemie $7 D007150
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a mitomycin $x farmakologie $7 D016685
- 650 _2
- $a ultrafialové záření $7 D014466
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a financování organizované $7 D005381
- 700 1_
- $a Lacina, Lukáš, $d 1979- $7 xx0106429
- 700 1_
- $a Lensch, M.
- 700 1_
- $a Smetana, Karel, $d 1958- $7 jn20000710554
- 700 1_
- $a Manning, J. C.
- 700 1_
- $a André, Sabine, $d 1966- $7 jn19990000189
- 700 1_
- $a Gabius, H. J.
- 773 0_
- $w MED00005439 $t Histology and histopathology $g Roč. 23, č. 2 (2008), s. 167-178 $x 0213-3911
- 910 __
- $a ABA008 $b x $y 7
- 990 __
- $a 20101022105432 $b ABA008
- 991 __
- $a 20101022105821 $b ABA008
- 999 __
- $a ok $b bmc $g 801334 $s 666077
- BAS __
- $a 3
- BMC __
- $a 2008 $b 23 $c 2 $d 167-178 $m Histology and histopathology $n Histol Histopathol $x MED00005439
- LZP __
- $a 2010-B/jtme